他氟前列素上市后的预算影响分析
|
摘要
目的:通过对他氟前列素进行上市后的预算影响分析,为药品报销目录的遴选、医保支付价格的决策及医疗机构用药方案的制定提供科学依据,以促进卫生资源的合理配置。方法:构建预算影响分析模型,测算他氟前列素在中国上市并进入医保目录对医保支出的预期影响。结果:如果2015年前列腺素类新药他氟前列素在中国上市并进入医保目录,由于其相对较低的日治疗费用,预计将会节约医保预算,估计到2019年将能节约的医保预算总费用为7 710万元。结论:他氟前列素上市并进入医保目录后将能够有效降低医保总支出,并且随着他氟前列素市场份额的增大,所能节约的医保费用将越来越大。
Objective: To conduct a budget impact analysis of tafluprost after its introduction into the market to provide scientific evidence for decision making process related to reimbursement formulary,reimbursement price,along with therapeutic regimen,and promote rational allocation of health resources. Methods: Budget impact analysis model was constructed to measure the expected changes in the expenditure of health care system after the adoption of tafluprost in China. Results: Due to its relatively low daily cost,tafluprost would save the budget after the adoption of tafluprost in China in the year of 2015. The total budget savings was expected to be 77. 10 million yuan in 2019. Conclusion: The adoption of tafluprost in China will save healthcare budget effectively and with the market share of tafluprost increasing,it will save more.
Objective: To conduct a budget impact analysis of tafluprost after its introduction into the market to provide scientific evidence for decision making process related to reimbursement formulary,reimbursement price,along with therapeutic regimen,and promote rational allocation of health resources. Methods: Budget impact analysis model was constructed to measure the expected changes in the expenditure of health care system after the adoption of tafluprost in China. Results: Due to its relatively low daily cost,tafluprost would save the budget after the adoption of tafluprost in China in the year of 2015. The total budget savings was expected to be 77. 10 million yuan in 2019. Conclusion: The adoption of tafluprost in China will save healthcare budget effectively and with the market share of tafluprost increasing,it will save more.
引文
[1]RINTARO SUZUKI JR E,MEIRELLES FRANKLIN L,BASILIO DA SILVA LJ,et al.Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension[J].Curr Med Res Opin,2006,22(9):1799-1805.
[2]林其敏.中国青光眼治疗药物使用及新药上市预算影响分析[D].北京:北京大学,2015.
[3]任泽钦.青光眼局部降眼压药专家共识和一线药物的发展[J].眼科,2012,21(1):11-13.
[4]中华医学会眼科学分会青光眼学组.我国原发性青光眼诊断和治疗专家共识(2014年)[J].中华眼科杂志,2014,50(5):382-383.
[5]胡春阳,韩晟,陈路佳,等.他氟前列素与拉坦前列素治疗原发性开角型青光眼的成本效果分析[J].中国新药杂志,2013,22(23):2831-2836.
[6]SONG HJ,KANG SH,HEO JH,et al.Cost effectiveness analysis of tafluprost compared with latanoprost on the treatment of primary open angle glaucoma in South Korea[J].Value Health,2009,12(7):A456-A457.
[7]MAKINO K,CHARLES H,TILDEN D,et al.Health economic evaluation of preservative-free tafluprost versus preserved latanoprost in the treatment of open-angle glaucoma or ocular hypertension(OH)[J].Value Health,2012,15(7):643.
[8]SULLIVAN SD,MAUSKOPF JA,AUGUSTOVSKI F,et al.Budget impact analysis—principles of good practice:report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force[J].Value Health,2014,17(1):5-14.
[9]MAUSKOPF JA,SULLIVAN SD,ANNEMANS L,et al.Principles of good practice for budget impact analysis:report of the ISPOR Task Force on good research practices—budget impact analysis[J].Value Health,2007,10(5):336-347.
[10]刘梭.基于人口预测模型的我国养老保险研究[D].合肥:安徽大学,2013.
[11]徐亮,陈建华,李建军,等.北京农村及城市特定人群原发性开角型青光眼的患病率调查及其筛查方法评价[J].中华眼科杂志,2004,40(11):9-15.
[12]HE M,FOSTER PJ,GE J,et al.Prevalence and clinical characteristics of glaucoma in adult Chinese:a population-based study in Liwan District,Guangzhou[J].Invest Ophthalmol Visual Sci,2006,47(7):2782-2788.
[13]张丽娟,单丽,樊攀,等.内蒙古开鲁县蒙古族原发性青光眼的患病率调查[J].内蒙古医学杂志,2010,42(7):817-819.
[14]SONG W,SHAN L,CHENG F,et al.Prevalence of glaucoma in a rural northern china adult population:a population-based survey in kailu county,inner mongolia[J].Ophthalmology,2011,118(10):1982-1988.
[15]QUIGLEY HA,BROMAN AT.The number of people with glaucoma worldwide in 2010 and 2020[J].Br J Ophthalmol,2006,90(3):262-267.
[16]VARMA R,LEE PP,GOLDBERG I,et al.An assessment of the health and economic burdens of glaucoma[J].Am J Ophthalmol,2011,152(4):515-522.
[17]徐玲,孟群.第五次国家卫生服务调查结果之二——卫生服务需要、需求和利用[J].中国卫生信息管理杂志,2014,11(3):193-194.
[18]中华人民共和国国家统计局.中国统计年鉴[M].北京:中国统计出版社,2013:95,767,854.
[2]林其敏.中国青光眼治疗药物使用及新药上市预算影响分析[D].北京:北京大学,2015.
[3]任泽钦.青光眼局部降眼压药专家共识和一线药物的发展[J].眼科,2012,21(1):11-13.
[4]中华医学会眼科学分会青光眼学组.我国原发性青光眼诊断和治疗专家共识(2014年)[J].中华眼科杂志,2014,50(5):382-383.
[5]胡春阳,韩晟,陈路佳,等.他氟前列素与拉坦前列素治疗原发性开角型青光眼的成本效果分析[J].中国新药杂志,2013,22(23):2831-2836.
[6]SONG HJ,KANG SH,HEO JH,et al.Cost effectiveness analysis of tafluprost compared with latanoprost on the treatment of primary open angle glaucoma in South Korea[J].Value Health,2009,12(7):A456-A457.
[7]MAKINO K,CHARLES H,TILDEN D,et al.Health economic evaluation of preservative-free tafluprost versus preserved latanoprost in the treatment of open-angle glaucoma or ocular hypertension(OH)[J].Value Health,2012,15(7):643.
[8]SULLIVAN SD,MAUSKOPF JA,AUGUSTOVSKI F,et al.Budget impact analysis—principles of good practice:report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force[J].Value Health,2014,17(1):5-14.
[9]MAUSKOPF JA,SULLIVAN SD,ANNEMANS L,et al.Principles of good practice for budget impact analysis:report of the ISPOR Task Force on good research practices—budget impact analysis[J].Value Health,2007,10(5):336-347.
[10]刘梭.基于人口预测模型的我国养老保险研究[D].合肥:安徽大学,2013.
[11]徐亮,陈建华,李建军,等.北京农村及城市特定人群原发性开角型青光眼的患病率调查及其筛查方法评价[J].中华眼科杂志,2004,40(11):9-15.
[12]HE M,FOSTER PJ,GE J,et al.Prevalence and clinical characteristics of glaucoma in adult Chinese:a population-based study in Liwan District,Guangzhou[J].Invest Ophthalmol Visual Sci,2006,47(7):2782-2788.
[13]张丽娟,单丽,樊攀,等.内蒙古开鲁县蒙古族原发性青光眼的患病率调查[J].内蒙古医学杂志,2010,42(7):817-819.
[14]SONG W,SHAN L,CHENG F,et al.Prevalence of glaucoma in a rural northern china adult population:a population-based survey in kailu county,inner mongolia[J].Ophthalmology,2011,118(10):1982-1988.
[15]QUIGLEY HA,BROMAN AT.The number of people with glaucoma worldwide in 2010 and 2020[J].Br J Ophthalmol,2006,90(3):262-267.
[16]VARMA R,LEE PP,GOLDBERG I,et al.An assessment of the health and economic burdens of glaucoma[J].Am J Ophthalmol,2011,152(4):515-522.
[17]徐玲,孟群.第五次国家卫生服务调查结果之二——卫生服务需要、需求和利用[J].中国卫生信息管理杂志,2014,11(3):193-194.
[18]中华人民共和国国家统计局.中国统计年鉴[M].北京:中国统计出版社,2013:95,767,854.